Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/17/2017 03/20/2017 03/21/2017 03/22/2017 03/23/2017 Date
7.15(c) 7.1(c) 7(c) 7.05(c) 7.25 Last
56 359 258 551 112 160 59 563 45 739 Volume
+1.42% -0.70% -1.41% +0.71% +2.84% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -56,9 M
Net income 2017 -56,1 M
Finance 2017 40,9 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -63,1 M
Net income 2018 -60,0 M
Finance 2018 74,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 118 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Is portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on CIDARA THERAPEUTICS INC
03/16 CIDARA THERAPEUTICS : reports 4Q loss
03/15 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Results of Operations and..
03/15 CIDARA THERAPEUTICS : Provides Corporate Update and Reports Fourth Quarter and F..
02/22 CIDARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and E..
02/22 IS THE CIDARA THERAPEUTICS INC (NASD : CDTX) Crash An Opportunity?
02/21 CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Regulation FD Disclosure
02/21 CIDARA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial St..
02/21 Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of C..
01/19 CIDARA THERAPEUTICS : Antimicrobials Working Group Announces New Leadership Team
01/12 CIDARA THERAPEUTICS : Completes Enrollment in Phase 2 RADIANT Trial Evaluating N..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/21$CDTX - GAP BREAKOUT -
1
03/20Cidara Therapeutics downgraded by Zacks Investment Research to sell.  
03/17Cidara Therapeutics's buy rating reiterated at Needham & Company LLC. $10.. 
03/16Wedbush Reiterates Outperform Rating for Cidara Therapeutics Inc $CDTX  
03/16Cidara Therapeutics's outperform rating reiterated at Wedbush. $13.00 PT.  
More tweets
Qtime:9
News from SeekingAlpha
03/15 Cidara Therapeutics misses by $0.09
02/21 Midday Gainers / Losers
02/21 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
02/21 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/21 Cidara's CD101 flunks mid-stage study in acute yeast infections; shares plumm..
Advertisement
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Full-screen chart
Technical analysis trends CIDARA THERAPEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 12,5 $
Spread / Average Target 78%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary & General Counsel
Taylor Sandison Chief Medical Officer & VP-Clinical Development
Theodore R. Schroeder Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS IN..-32.21%118
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results